Targeting EGFR and ERBB3 in lung cancer patients: Clinical outcomes in a phase I trial of MM-121 in combination with erlotinib.

被引：0
|
作者：
Sequist, Lecia V.
Modiano, Manuel R.
Rixe, Olivier
Jackman, David Michael
Andreas, Karen
Pearlberg, Joseph
Moyo, Victor M.
Harb, Wael A.
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Arizona Clin Res Ctr, Tucson, AZ USA
[3] Univ Cincinnati, Cincinnati, OH USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Merrimack Pharmaceut, Cambridge, MA USA
[6] Sanofi Oncol, Cambridge, MB, Canada
[7] Horizon Oncol Ctr, Lafayette, IN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7556
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
    Kobayashi, Takashi
    Koizumi, Tomonobu
    Agatsuma, Toshihide
    Yasuo, Masanori
    Tsushima, Kenji
    Kubo, Keishi
    Eda, Seiichiro
    Kuraishi, Hiroshi
    Koyama, Shigeru
    Hachiya, Tsutomu
    Ohura, Nariaki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1241 - 1246
  • [42] A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
    Takashi Kobayashi
    Tomonobu Koizumi
    Toshihide Agatsuma
    Masanori Yasuo
    Kenji Tsushima
    Keishi Kubo
    Seiichiro Eda
    Hiroshi Kuraishi
    Shigeru Koyama
    Tsutomu Hachiya
    Nariaki Ohura
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1241 - 1246
  • [43] Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression
    Reguart, Noemi
    Rosell, Rafael
    Cardenal, Felipe
    Cardona, Andres F.
    Isla, Dolores
    Palmero, Ramon
    Moran, Teresa
    Rolfo, Christian
    Pallares, M. Cinta
    Insa, Amelia
    Carcereny, Enric
    Majem, Margarita
    De Castro, Javier
    Queralt, Cristina
    Molina, Miguel A.
    Taron, Miquel
    LUNG CANCER, 2014, 84 (02) : 161 - 167
  • [44] Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer
    Falchook, Gerald S.
    Naing, Aung
    Hong, David S.
    Zinner, Ralph
    Fu, Siqing
    Piha-Paul, Sarina A.
    Tsimberidou, Apostolia M.
    Morgan-Linnell, Sonia K.
    Jiang, Yunfang
    Bastida, Christel
    Wheler, Jennifer J.
    Kurzrock, Razelle
    ONCOTARGET, 2013, 4 (01) : 118 - 127
  • [45] Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer
    Spigel, David R.
    Ervin, Thomas J.
    Ramlau, Rodryg A.
    Daniel, Davey B.
    Goldschmidt, Jerome H., Jr.
    Blumenschein, George R., Jr.
    Krzakowski, Maciej J.
    Robinet, Gilles
    Godbert, Benoit
    Barlesi, Fabrice
    Govindan, Ramaswamy
    Patel, Taral
    Orlov, Sergey V.
    Wertheim, Michael S.
    Yu, Wei
    Zha, Jiping
    Yauch, Robert L.
    Patel, Premal H.
    Phan, See-Chun
    Peterson, Amy C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (32) : 4105 - +
  • [46] Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer
    Bhateja, Priyanka
    Dowlati, Afshin
    Sharma, Neelesh
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (03) : 435 - 441
  • [47] Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer
    Priyanka Bhateja
    Afshin Dowlati
    Neelesh Sharma
    Investigational New Drugs, 2018, 36 : 435 - 441
  • [48] PHASE I STUDY OF PATRITUMAB (U3-1287) IN COMBINATION WITH ERLOTINIB IN JAPANESE PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Murakami, H.
    Yamamoto, N.
    Kudo, K.
    Nishio, M.
    Kaneda, H.
    Nakagawa, K.
    Horinouchi, H.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2013, 24
  • [49] A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG plus ), locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Sequist, L. V.
    Anderson, I.
    Bauer, T. M.
    Demars, N.
    Felip, E.
    Frost, N.
    Harb, W.
    Horn, L.
    Huber, R. M.
    Kudla, A. J.
    Lee, J.
    Mathews, S.
    Mehra, R.
    Nieva, J.
    Perol, M.
    Shepherd, F.
    Spira, A.
    Czibere, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [50] PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer
    Propper, David J.
    Gao, Fangfei
    Saunders, Mark P.
    Sarker, Debashis
    Hartley, John A.
    Spanswick, Victoria J.
    Lowe, Helen L.
    Hackett, Louise D.
    Ng, Tony T.
    Barber, Paul R.
    Weitsman, Gregory E.
    Pearce, Sarah
    White, Laura
    Lopes, Andre
    Forsyth, Sharon
    Hochhauser, Daniel
    BRITISH JOURNAL OF CANCER, 2023, 128 (02) : 245 - 254
12345